These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11119809)

  • 1. Effective strategies to prevent cytomegalovirus disease after renal transplantation.
    Chapman JR
    Transplant Proc; 2000 Nov; 32(7):1508-9. PubMed ID: 11119809
    [No Abstract]   [Full Text] [Related]  

  • 2. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation.
    Jung C; Engelmann E; Borner K; Offermann G
    Transplant Proc; 2001; 33(7-8):3621-3. PubMed ID: 11750538
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylactic cytomegalovirus management strategies.
    Martin M
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):23-7. PubMed ID: 7482812
    [No Abstract]   [Full Text] [Related]  

  • 4. Preemptive ganciclovir therapy in renal transplantation.
    Brennan DC; Storch GA; Lippman BJ
    Ann Intern Med; 1996 Apr; 124(7):693. PubMed ID: 8607602
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir.
    Paniagua MJ; Crespo-Leiro MG; De la Fuente L; Tabuyo T; Mosquera I; Cañizares A; Naya C; Fariña P; Juffé A; Castro-Beiras A
    Transplant Proc; 2002 Feb; 34(1):69-70. PubMed ID: 11959189
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus infection in marrow transplantation.
    Boeckh M; Bowden R
    Cancer Treat Res; 1995; 76():97-136. PubMed ID: 7577347
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment and prevention of cytomegalovirus in renal transplant patients: weighing the evidence.
    Hakkert A; Dykeman-Sharpe J
    CANNT J; 2003; 13(3):69-73; quiz 74-5. PubMed ID: 14596201
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins.
    Séchet A; Bridoux F; Bauwens M; Ayache RA; Belmouaz S; Touchard G
    Transplant Proc; 2002 May; 34(3):812-3. PubMed ID: 12034192
    [No Abstract]   [Full Text] [Related]  

  • 9. Ganciclovir-resistant cytomegalovirus.
    Legendre C
    Lancet; 2000 Oct; 356(9238):1356. PubMed ID: 11073050
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of preemptive gancyclovir therapy in the prevention of cytomegalovirus infections in high-risk renal graft recipients.
    Chak WL; Choi KS; Wong KM; Chan YH; Chau KF; Li CS
    Transplant Proc; 2003 Feb; 35(1):280-1. PubMed ID: 12591399
    [No Abstract]   [Full Text] [Related]  

  • 11. Ganciclovir prophylaxis of cytomegalovirus disease.
    Conti DJ; Shen G; Singh T; Isenberg A; Freed BM
    Transplant Proc; 1997; 29(1-2):804-6. PubMed ID: 9123534
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylaxis of cytomegalovirus disease with intravenous ganciclovir in renal transplantation.
    Sancho A; Górriz JL; Crespo JF; Avila A; Alcaraz MJ; García Ramos JL; Pallardó LM
    Transplant Proc; 1999 Sep; 31(6):2337-8. PubMed ID: 10500606
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.
    Kuypers DR; Vanrenterghem YF
    Nephrol Dial Transplant; 1999 Oct; 14(10):2304-8. PubMed ID: 10528649
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection after liver transplantation using different prophylaxes.
    Kornberg A; Grube T; Hommann M; Schotte U; Scheele J
    Transplant Proc; 2001; 33(7-8):3624-5. PubMed ID: 11750539
    [No Abstract]   [Full Text] [Related]  

  • 17. Ganciclovir for cytomegalovirus infection in renal transplant recipients.
    Lancet; 1989 Jan; 1(8631):216-7. PubMed ID: 2563118
    [No Abstract]   [Full Text] [Related]  

  • 18. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir.
    Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P
    Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766
    [No Abstract]   [Full Text] [Related]  

  • 19. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
    Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.